	EALTH AND HUMAN SERVICES			
DISTRICT OFFICE ADDRESS AND PHONE NUMBER Food and Drug Administration		DATE(S) OF INSPECTION 24 - 28 July 2017		
4040 N. Central Expy Ste 300 Dallas, TX 75204 214-253-5200		EI NUMBER		
Industry Information: www.fda.gov/oc/industry NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED		010836489		
TO: Ms. Sara A. Herrington - President and Owner				
FIRM NAME STREET ADDRESS				
I.V. Specialty Ltd.	3200 Steck Ave., Suite 330			
CITY, STATE AND ZIP CODE TYPE OF ESTABLISHMU				
Austin, TX 78757 Producer of Sterile Drugs HIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL				
OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMIN/ OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CO OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING TH YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMB	DRRECTIVE ACTION IN RESPONSE IE INSPECTION OR SUBMIT THIS INF	TO AN OBSERVATION, '	YOU MAY DISCUSS THE	
DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:				
OBSERVATION 1				
Vermin was observed present in areas immediately a	djacent to your production	area.		
A dead spider was observed in HEPA filter located in from the ISO 5 laminar air flow (LAF) hood used for	e	lean room, appro	ximately 10 feet	
OBSERVATION 2				
The ISO-classified have difficult to clean, particle-ge	enerating, or visibly dirty e	quipment or surfa	ices.	
A. LAF Hood ^{(b) (4)} has loose panels covering a light find difficult to clean surface. This equipment is intended drugs.				
B. LAF Hood ^{(b) (4)} has a loose access panel immediate clean surface. This equipment is intended to create an			es a difficult to	
C. Dirt, debris, stains, and one strand of hair proxima immediately below the aseptic processing surface of	tely 2 inches long was obs the ISO 5 hood.	served in the front		
D. LAF Hood ^{(b)(4)} is installed on a wood fiber board to This multi-surface table creates a difficult to sanitize			a-type surfaces.	
E. There is a office style telephone that creates a diffi			he wiring for the	
telephone was observed on the floor behind the shelf,				
F. The supply and return air ducts are both located in			9 m	
pharmacist stated this room is intended to meet ISO 7				
G. The door to the ISO 7 clean room is constructed o	t a wood laminate approxi	mately 15 feet aw	ray from the ISO	
EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TITLE (P	rint or Type)	DATE ISSUED	
SEE REVERSE OF THIS PAGE	Scott Ballard, Investigator			
OF THIS PAGE	Nimmy Mathews, Investigator		07/28/2017	

FORM FDA 483 (9/08) PREVIOUS EDITION OBSOLETE

-					
DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT OFFICE ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION	DATE(S) OF INSPECTION			
Food and Drug Administration 4040 N. Central Expy Ste 300	24 - 28 July 2017	24 - 28 July 2017			
Dallas, TX 75204	FEI NUMBER	FEI NUMBER			
214-253-5200	3010836489				
Industry Information: www.fda.gov/oc/industry NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED					
TO: Ms. Sara A. Herrington - President and Owner					
FIRM NAME	M NAME STREET ADDRESS				
Specialty Ltd. 3200 Steck Ave., Suite 330					
CITY, STATE AND ZIP CODE	TYPE OF ESTABLISHMENT INSPECTED				
Austin, TX 78757	Producer of Sterile Drugs				
5 LAF Hood used for processing sterile drugs. This wood laminate creates a difficult to sanitize surface in the clean room. H. The ceiling of the ISO 7 clean room has a tear in the plastic surface of the drop-ceiling tile approximately 13 feet from the LAF Hood used for processing sterile drugs. This tear exposes the dry-wall material behind the plastic layer.					
Note: Items C, D, E, F, and G are repeat observations from the Inspection in February 2016					
OBSERVATION 3					
Aseptic practices in critical area are not adequate for s	sterile drug processing. On 25 July 2017, w	e observed:			
A. The pharmacist touching item on floor and return to processing TPN products without changing gloves. B. The pharmacist using a bar code scanner from outside hood and return to processing without sanitizing gloves.					
OBSERVATION 4					
Cleaning or Sanitizing of ISO 7 clean room is not ade	quate. On 25 July 2017, we observed:				
A. Pharmacist did not use a top-down approach to daily cleaning, the floor was cleaned first, then preparation tables. The bottom shelf of the preparation table was not sanitized where the (b) (4) pump is stored and the legs of the (b) (4) pump were not sanitized. B. The container labeled "Sterile Water" in the clean room is not sterile. Additionally, the container does not have an expiration date, instead a fill date is written on the container. Your pharmacist stated that he fills the bottle with sterile water (b) (4) and uses it to clean "caked" on residue after production in the LAF hood and clean room. C. The sanitized used in the ISO 7 and ISO 8 rooms ((b) (4)) is a non-sterile disinfectant.					
EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TITLE (Print or Type)	DATE ISSUED			
SEE to returk	Scott Ballard, Investigator				
REVERSE OF THIS PAGE	Nimmy Mathews, Investigator	07/28/2017			

FORM FDA 483 (9/08) PREVIOUS EDITION OBSOLETE

		HEALTH AND HUMAN SERVICES		
DISTRICT OFFICE ADDRESS AND PHONE NUMBER		DATE(S) (DATE(S) OF INSPECTION	
Food and Drug Administration 4040 N. Central Expy Ste 300 Dallas, TX 75204 214-253-5200		24 - 28	July 2017	
			FEI NUMBER 3010836489	
	rmation: www.fda.gov/oc/industry E OF INDIVIDUAL TO WHOM REPORT IS ISSUED	501005		
TO: Ms. San	a A. Herrington - President and Owner			
FIRM NAME	M NAME STREET ADDRESS			
I.V. Specialt	I.V. Specialty Ltd. 3200 Steck Ave., Suite			
CITY, STATE AND ZIP CODE TYPE OF ESTABLISHMENT		TYPE OF ESTABLISHMENT INSPECTED	5	
Austin, TX	78757	Producer of Sterile Drugs		
	TION 5 surance is not adequate nples collected inside the ISO 5 LAF He	ood on (b) (4) basis are not incu	ubated at (b) (4)C per	
	er instruction. We observed the plates b		" without an incubator at	
OBSERVA	TION 6			
	ified areas were not certified under dyn der operational conditions, based on vid			
	EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TITLE (Print or T)	DATE ISSUED	
SEE REVERSE OF THIS PAGE	Ma Bul			
	and	Scott Ballard, Investigator Nimmy Mathews, Investigator	07/28/2017	
ODM EDA 104				
ORM FDA 483	(9/08) PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS	Page 3 of 3	